Sermo Reports Week 3 Results: Globally 17% Point Increase in COVID Treaters Who Have Used Hydroxychloroquine (33%-50%) and Azithromycin (41%-58%) Percentage of New York Physicians Who Have Used Hydroxychloroquine Nearly Doubled, Italian and French Physicians Jumped 30% Points + Over 2 Weeks Plasma Still Perceived as Most Effective but Not Widely Used Perception of Hydroxychloroquine’s Efficacy is Significantly Higher Among Physicians in Europe and China vs US Physicians (50% vs 29%) (Graphic: Business Wire) April 15, 2020 11:42 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Week three data of the Barometer study from 4016 physicians in 30 countries conducted by Sermo reveals the emergence of treatment patterns and efficacy perceptions. Sermo, the largest global healthcare polling company and social platform for physicians, has published unrestricted access to the results of its Real Time Barometer study on sermo.com. Key findings: In Wave 3 we explored perceptions of physicians who were high vs moderate vs low treaters of COVID patients. The total number of physician respondents for Wave 3 was 4016. Of those, 33% treated COVID patients (n=1337). The COVID treaters (1337) breakdown was: 42% of COVID treaters have treated between 1-5 patients 20% of COVID treaters have treated between 6 -10 patients 38% of COVID treaters have treated between 11 and more patients We did not find significant differences between highly active and low active COVID treaters in the below findings. Usage patterns among COVID treaters (N= 1337) The top three treatments that doctors reported having prescribed were Azithromycin (58%), Hydroxychloroquine (50%), and Bronchodilators (48%); traditional Chinese medicine has been used by 67% of physicians in China. Week over week increases in usage Percentage of physicians in New York who have used Hydroxychloroquine nearly doubled since Wave 1 week of March 25 (23% to 40% to 43% wave over wave). Italy and France had the highest increase in COVID treaters having prescribed Hydroxychloroquine wave over wave; an increase from 50% to 83% for Italy and an increase from 20% to 50% for France. The number of COVID treaters that report having used Hydroxychloroquine and Azithromycin both increased 17% points since Wave 1 the week of March 25. Hydroxychloroquine Wave 1: 33%, Wave 2: 44%, Wave 3: 50% Azithromycin Wave 1: 41%, Wave 2: 50%, Wave 3: 58% The number of COVID treaters that report having used Bronchodilators increased 12% points (from 36% to 48%) week over week. Usage of anti-HIV drugs (e.g. Lopinavir plus Ritonavir), drugs to treat the flu (e.g. Oseltamivir), and plasma from recovered patients remains steady week over week, while use of non-approved drugs (e.g. Remdesivir) decreased slightly. Perceived treatment efficacy Physicians who treat COVID patients in Italy, Spain, France, and China have higher perceptions of Hydroxychloroquine’s efficacy vs the US (~50% vs 29%). The top treatments that have been used/seen used and reported as very or extremely effective among COVID treaters (N= 1337) include: 46% plasma from recovered patients (n=363); 40% Hydroxychloroquine (n=875); 38% high dose steroids during a cytokine storm (n=556) No significant differences of perceived efficacy were observed between highly active COVID treaters and users of these drugs (physicians treating 11+ patients) and lower active COVID treaters (1-10 patients) 55% of physicians in China who have used traditional Chinese medicine rated traditional Chinese medicine as effective or extremely effective Most popular Hydroxychloroquine dosage regimen 75% report using 400mg BID on day one (800mg total), then 400 mg daily for 4-5 days 10% report using 600mg BID on day one (1,200mg total), then 400 mg daily for 4 days Methodology Most results are reported for individual countries with a minimum sample size of 250. A sample size of 250 point estimates have a precision of a +/- 6% precision at a 94% confidence level. Where sample sizes are smaller, N sizes are noted. Thirty countries included in the study are the United States, Canada, Argentina, Brazil, Mexico, Germany, Italy, the United Kingdom, France, Spain, Belgium, the Netherlands, Sweden, Turkey, Poland, Russia, Finland, Ireland, Switzerland, Austria, Denmark, Norway, Greece, Taiwan, Japan, South Korea, Australia, China, India, and Hong Kong. No incentive was offered to respondents. Full methodology. About Sermo Sermo is the largest healthcare data collection company and social platform for physicians, reaching 1,3MM HCPs across 150 countries. The platform enables doctors to anonymously talk real-world medicine, review treatment options via our proprietary Drug Ratings platform, collectively solve patient cases, and participate in medical market research. For more information, visit sermo.com. https://www.businesswire.com/news/home/20200415005517/en/Sermo-Reports-Week-3-Results-Globally-17
"The number of people who have been saved by the use of this medicine is impossible to count" because the proven number is ZERO. It would be great to have studies prove hydroxychloroquine based therapy is an effective treatment for COVID-19, but the initial results of proper studies have not been promising. I support doctors using it experimentally and I support studies looking at its effectiveness (and long as all the money for studies of other medicines are not robbed). But hydroxychloroquine or any other medication should not be hyped by politicians and media pundits as a proven cure for COVID-19. Let the medical community handle it properly.
More TDS. There are plenty of people who have been about to die that were saved after taking this drug. Does it work for everyone, most likely not. Does it work better with an antibiotic, seems to be. In the meantime while you wait for your studies many people have been saved. I am just throwing this to show what TDS can do to a brain.
Actually among the severely ill cohort is where hydroxychloroquine based therapy has been proven to have no benefit. In New York, 80% of the COVID-19 patients who are intubated die. The rate is the exact same for those where hydroxychloroquine based therapy was used and for those where it was not. The death rates among the severely ill intubated patients in Europe and Asia show a similar mortality rate - and hydroxychloroquine based therapy does not change the rate. Your statement "here are plenty of people who have been about to die that were saved after taking this drug" is completely false and the medical evidence backs it as not being correct. The only question now is if hydroxychloroquine based therapy provides improvement in the results for mildly ill hospitalized COVID-19 patients.
https://www.sermo.com/ is looking as a very legit non-political organization. gwb-trading obviously knows better than a cohort of doctors. Some people are truly ridiculous. The number of COVID treaters that report having used Hydroxychloroquine and Azithromycin both increased 17% points since Wave 1 the week of March 25. Hydroxychloroquine Wave 1: 33%, Wave 2: 44%, Wave 3: 50% Azithromycin Wave 1: 41%, Wave 2: 50%, Wave 3: 58% Yep, according to gwb-trading, all these doctors prescribing Hydroxychloroquine and Azithromycin are doing it out of wack.
For your review before you jump on the Remsdivir band wagon. https://www.marketwatch.com/amp/story/guid/F857E1C4-A254-47D4-8B87-04955D4FC31A
My assertion comes from the actual patients who have used that phrase to recount their ordeal. If Hydroxychoroquine has kept thousands of people from having to be taken to the ICU and be intubated in the first place, then yes, we can safely say Hydroxychoroquine has saved many lives.
Yes ..... Remdesivir has faded as being effective, this can also be seen in recent Sermo summaries. It only worked (possibly) when used jointly with Interferon. It seems likely that Remdesivir is not a "cure" for COVID-19. The medical community should keep driving to determine the best treatment for COVID-19 and continue with relevant studies. The medical community will determine the most effective treatment quickly if they are left to do their scientific work without interference from politicians and media pundits.
The doctors prescribing hydroxychloroquine and azithromycin are doing it as an experimental treatment for COVID-19. They are studying the results of this treatment in many trials. The medical community does not believe hydroxychloroquine and azithromycin is a proven cure; nor do they promote it as such. Currently the evidence is that hydroxychloroquine and azithromycin does not provide any benefit for severely ill COVId-19 patients (as outlined in multiple studies that have been posted). The only question now is if hydroxychloroquine and azithromycin provide any benefit for mild/moderately ill hospitalized COVID-19 patients.